The US FDA approved KBP-7026 to enter Phase I clinical trial

Jinan, China and Princeton, New Jersey, USA (Feb 18, 2015) KBP BioSciences, a clinical stage biotech company with operations in China, US, and Singapore, today announced that the US FDA approved KBP-7026 to enter clinical trials for the potential treatment of respiratory diseases such as asthma and COPD.
Asthma and COPD affect tens of millions of patients worldwide. Billions of dollars are spent on the treatment of these diseases each year without much outcome improvements.
“KBP-7026 is a potent anti-inflammatory agent that can be used effectively against inflammatory diseases such as asthma and COPD.” Said Zhenhua Huang, President of KBP. “One major advantage of KBP-7026 is that it offers a wide treatment window.”
Many investigational therapies for COPD and asthma due to lack of efficacy at the tolerable dose. KBP-7026 has a much wider therapeutic window, allowing a better chance to show clinical benefits.
Previously in December 2014, the China FDA accepted the IND application of KBP-7026. Then in January 2015, the US FDA accepted IND application of KBP-7026.